ELAB

Proposed Mice2Space spaceflight study would evaluate EL-22 and EL-32 in mice in a real-world microgravity environment, targeting one of the most significant physiological challenges of spaceflight Three-part relationship would expand PMGC’s footprint in the growing commercial space economy through a preferred U.S. manufacturing role for A&B Aerospace and a planned strategic investment in Orbit2Orbit NEWPORT BEACH, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") is pleased to announce that it has entered into a non-binding term sheet with Orbit2Orbit Pty Ltd ("Orbit2Orbit" or "O2O"), an Australia-headquartered space technology company,

New Filings Extend EL-22 and EL-32 into Spaceflight-Associated Muscle Atrophy, Broadening NorthStrive’s Myostatin and Activin A Intellectual Property Portfolio Across Human Weight-Loss, Space Health and Animal Health Applications The filings are intended to position EL-22 and EL-32 as potential muscle-preservation platforms not only for large terrestrial markets, but also for the emerging medical requirements associated with sustained human presence in space NEWPORT BEACH, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), today announced the filing

NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it will effect a 1-for-10 reverse stock split (the "Split") of its issued and outstanding and authorized common stock, par value $0.0001 per share ("Common Stock"), effective at 12:00 am, Eastern time, on August 21, 2026. Key Details of the Reverse Stock Split: Conversion Ratio: Every 10 shares of issued and outstanding Common Stock will be consolidated into one share of Common Stock, and every 10 shares of authorized Common Stock will be consolidated into one share of Common Stock, each with no further action required from shareholders.Fractional Share

10-Q - PMGC Holdings Inc. (0001840563) (Filer)

NEWPORT BEACH, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the "Quarterly Report") for the three and six months ended June 30, 2026, with the U.S. Securities and Exchange Commission ("SEC"). The Quarterly Report is available on the SEC's website at www.sec.gov under the Company's filings. Q2 2026 was a quarter of meaningful revenue and balance sheet growth, driven by the Company's operating platform and continued M&A execution, including the closing of the A&B Aerospace, Inc. ("A&B Aerospace") acquisition on May 11, 2026. A&B Aerospace is an AS9100D-certif

NEWPORT BEACH, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company, today confirmed that it is in compliance with Nasdaq’s newly approved Market Value of Listed Securities ("MVLS") continued-listing requirement and announced that it is working with third-party market-data providers to correct inaccurate share count and market capitalization data currently displayed for the Company. The Company is aware that certain third-party market-data websites are displaying an incorrect number of PMGC’s issued and outstanding shares. As of July 29, 2026, PMGC has 8,095,835 shares of common stock issued and outstan

NEWPORT BEACH, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), a diversified holding company executing a precision manufacturing growth strategy across the aerospace and defense supply chain, today announced that its wholly owned subsidiary, A&B Aerospace, Inc. ("A&B Aerospace"), has entered into a Long-Term Agreement (the "Agreement") with Precision Aerospace & Defense Group, Inc. ("PAD Group") to manufacture and supply precision-machined aerospace and defense components. The Agreement, effective July 23, 2026, establishes a two-year framework under which PAD Group and its subsidiaries may issue purchase orders to A&B Ae

NEWPORT BEACH, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB), today announced that it has entered into a project services agreement with Deploy360 to conduct independent validation and testing of the patented GPS-denied autonomous navigation technology currently under option by NorthStrive Defense Tech. The project is intended to provide NorthStrive Defense Tech with an independent technical assessment of the technology’s software, architecture, dependencies, and performance under controlled, simulation-based conditions. The technology is covered by U.S. Pa

Definitive license agreement formalizes exclusive, worldwide, sublicensable rights to patented multi-domain drone payload technology for aerospace and defense applicationsAgreement follows the binding term sheet and sponsored research agreement announced earlier this yearLicense covers U.S. Patent No. 12,291,334 and related know-how, with a multi-year development plan targeting prototype completion, non-dilutive funding applications, and first commercial sale NEWPORT BEACH, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB) formed to license and commercialize def

Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd. Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists NEWPORT BEACH, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), today announced plans to ini

8-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

Strategic consolidation of two precision manufacturing portfolio companies expected to streamline operations, shared resources, and strengthen the companies’ aerospace manufacturing platform NEWPORT BEACH, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it has merged AGA Precision Systems LLC ("AGA") into A&B Aerospace, Inc. ("A&B Aerospace"), with A&B Aerospace expected to be the surviving operating entity. The merger is designed to simplify PMGC’s aerospace precision manufacturing platform by consolidating two related businesses under one corporate structure. Following the merger, AGA will cease to exist as a sep

DENVER, July 01, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Three emerging biotechnology companies—Can-Fite BioPharma (NYSEAMERICAN: CANF), NeOnc Technologies (NASDAQ:NTHI), and PMGC Holdings (NASDAQ:ELAB) through its NorthStrive Biosciences subsidiary, are pursuing a distinct therapeutic strategy, the common theme is execution. Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the second half of 2026. Can-Fite BioPharma Reports Encouraging Pancreatic Cancer Survival Data While Preparing Next Clinical Stage Can-Fite BioPharma (NYSEAMERICAN

8-K - PMGC Holdings Inc. (0001840563) (Filer)

Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism.Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development. NEWPORT BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic partner Yuv

Filed applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight lossFiled applications include combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support NEWPORT BEACH, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that its wholly-owned subsidiary, NorthStrive Biosciences, Inc. ("NorthStrive"), has filed two new U.S. patent applications expanding the Company's EL-22 and EL-32 intellectual property portfolio into potential human pharmaceutical

A&B Aerospace, SVM Machining, and AGA Precision Systems Position PMGC's Precision Manufacturing Platform to Serve Growing Demand Across Satellites, Launch Systems, and Space Infrastructure, such as Space Data Centers NEWPORT BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), a diversified holding company, highlights that its current precision manufacturing operating subsidiaries currently serve and have the opportunity to further capitalize of the current Space exploration industry growth. PMGC's wholly owned operating companies positioned to serve the space economy include A&B Aerospace, Inc. ("A&B Aerospace"), SVM M

8-K - PMGC Holdings Inc. (0001840563) (Filer)

Binding term sheet for an exclusive, worldwide, sublicensable license in the aerospace and defense field to a granted U.S. patent covering autonomous, buoyancy-assisted transport of payloads across air and water NEWPORT BEACH, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB), today announced entry into a binding term sheet for an exclusive, worldwide, sublicensable license, within the aerospace and defense technologies field, to a patented multi-domain drone payload technology covered by U.S. Patent No. 12,291,334. The technology enables an aerial vehicle to au

8-K - PMGC Holdings Inc. (0001840563) (Filer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)